AU3121497A - Methods of treating type i hypersensitivity using monophosphoryl lipid - Google Patents

Methods of treating type i hypersensitivity using monophosphoryl lipid

Info

Publication number
AU3121497A
AU3121497A AU31214/97A AU3121497A AU3121497A AU 3121497 A AU3121497 A AU 3121497A AU 31214/97 A AU31214/97 A AU 31214/97A AU 3121497 A AU3121497 A AU 3121497A AU 3121497 A AU3121497 A AU 3121497A
Authority
AU
Australia
Prior art keywords
mla
hypersensitivity
monophosphoryl lipid
methods
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31214/97A
Other languages
English (en)
Inventor
Jerry Dolovich
Jean S. Marshall
J. Terry Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of AU3121497A publication Critical patent/AU3121497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU31214/97A 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid Abandoned AU3121497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08645672 1996-05-14
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
AU3121497A true AU3121497A (en) 1997-12-05

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31214/97A Abandoned AU3121497A (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid

Country Status (11)

Country Link
US (1) US5762943A (enExample)
EP (1) EP0914114B1 (enExample)
JP (1) JP4105230B2 (enExample)
AT (1) ATE249824T1 (enExample)
AU (1) AU3121497A (enExample)
CA (1) CA2252604C (enExample)
DE (1) DE69724970T2 (enExample)
DK (1) DK0914114T3 (enExample)
ES (1) ES2205231T3 (enExample)
PT (1) PT914114E (enExample)
WO (1) WO1997042947A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
CA2333578C (en) * 1998-07-14 2010-11-16 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
EP1113818B1 (en) * 1998-09-18 2006-05-17 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
EP1671646A3 (en) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
CA2767116A1 (en) 1999-05-13 2000-11-23 Wyeth Holdings Corporation Adjuvant combination formulations
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
BR0110975A (pt) * 2000-05-19 2004-03-23 Corixa Corp Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
KR100863368B1 (ko) * 2000-11-10 2008-10-13 와이어쓰 홀딩스 코포레이션 조합 보조 제제
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
WO2011137422A2 (en) * 2010-04-30 2011-11-03 Apellis Pharmaceuticals, Inc. Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2935722A1 (en) * 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
BR112017022585A2 (pt) * 2015-05-01 2018-07-17 Nitto Denko Corporation composição de vacina de alergia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
WO1993015766A1 (en) * 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
PT914114E (pt) 2004-02-27
DE69724970T2 (de) 2004-07-22
JP4105230B2 (ja) 2008-06-25
CA2252604A1 (en) 1997-11-20
EP0914114A1 (en) 1999-05-12
US5762943A (en) 1998-06-09
WO1997042947A1 (en) 1997-11-20
DK0914114T3 (da) 2003-10-20
ATE249824T1 (de) 2003-10-15
CA2252604C (en) 2009-09-08
EP0914114B1 (en) 2003-09-17
DE69724970D1 (de) 2003-10-23
ES2205231T3 (es) 2004-05-01
JP2000510844A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
AU3121497A (en) Methods of treating type i hypersensitivity using monophosphoryl lipid
EP0735893A4 (en) CHANGING THE IMMUNE RESPONSE BY USING PAN DR BINDING PROTEINS
DE69511379D1 (en) Immunogens gegen gonadotropin releasing hormone
AU1809495A (en) Composition and method for preventing and treating inflammation with immunoglobulin a
KR970706013A (ko) 암에 대해 면역학적 치료활성이 있는 스트레스 단백질-펩티드 복합체 (immunotherapeutic stress protein-peptide complexes against cancer)
EP1393730A3 (en) Combination chemotherapy involving topotecan and a platinum coordination compound
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
AU7460896A (en) Composition and methods for enhancing immune responses mediated by antigen-presenting cells
AU8239298A (en) Nucleotide-comprising composition
EP1340502A3 (en) Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0837692A4 (enExample)
AU7161098A (en) Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
FI956028A0 (fi) Estreenisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
EP0282343A3 (en) Method to stimulate the immune response to specific antigens
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
AU3991899A (en) Verotoxin b subunit for immunization
IE871769L (en) Fluorooxirane carboxylates
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
AU5994596A (en) Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising fro m exposure to an antigen
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
CA2170142A1 (en) Composition and method for stimulation of reproductive performance
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
AU8501191A (en) Cross-reactive influenza a immunization
WO2000032223A3 (en) Therapeutic treatment with immunogenic drugs